CYTOKINETICS INC [CYTK] Filings

10-Q 1 cytk-20240930.htm 10-Q 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-50633

CYTOKINETICS, INCORPORATED

(Exact name of registrant as specified in its charter)


Delaware	94-3291317
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

350 Oyster Point Blvd. South San Francisco, California	94080
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (650) 624-3000

Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
 
Common Stock, $0.001 par value

    Trading symbol
 
CYTK

    Name of each exchange on which registered
 
The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☑		Accelerated filer ☐		Non-accelerated filer ☐		Smaller reporting company ☐		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of common stock, $0.001 par value, outstanding as of November 5, 2024: 118,014,240

Table of Contents

CYTOKINETICS, INCORPORATED

TABLE OF CONTENTS FOR FORM 10-Q

FOR THE three and nine months ended September 30, 2024


	Page
Glossary of Terms	3

PART I. FINANCIAL INFORMATION	7
Item 1. Financial Statements (Unaudited)	7
Condensed Consolidated Balance Sheets	7
Condensed Consolidated Statements of Operations and Comprehensive Loss	8
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity	9
Condensed Consolidated Statements of Cash Flows	11
Notes to Condensed Consolidated Financial Statements	12
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3. Quantitative and Qualitative Disclosures About Market Risk	45
Item 4. Controls and Procedures	46

PART II. OTHER INFORMATION	47
Item 1. Legal Proceedings	47
Item 1A. Risk Factors	47
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	76
Item 3. Defaults Upon Senior Securities	76
Item 4. Mine Safety Disclosures	76
Item 5. Other Information	76
Item 6. Exhibits	77

SIGNATURES	79

Table of Contents

Glossary of Terms

Unless the context requires otherwise, references to “Cytokinetics,” “the Company,” “we,” “us” or “our” in this Quarterly Report on Form 10-Q refer to Cytokinetics, Incorporated and its subsidiaries. References to “Notes” in this Form 10-Q are to the Notes to the Condensed Consolidated Financial Statements in this Form 10-Q. We also have used other specific terms in this Form 10-Q, most of which are explained or defined below:


Term/Abbreviation		Definition
2004 Plan		Cytokinetics’ Amended and Restated 2004 Equity Incentive Plan
2020 RTW Transactions		The transactions contemplated by the RTW Royalty Purchase Agreement, Corxel Aficamten License Agreement and the Common Stock Purchase Agreements, dated July 14, 2020, by and between Cytokinetics and the RTW Investors
2021 RTW Transactions		The transactions contemplated by the Corxel OM License Agreement and the Common Stock Purchase Agreements, dated December 20, 2021 by and between Cytokinetics and the RTW Investors
2022 RPI Transactions		The transactions contemplated by the RP Multi Tranche Loan Agreement and the RP Aficamten RPA
2024 RPI Transactions		The transactions contemplated by the 2024 RP OM Loan Agreement, the RP CK-586 RPA, the RP Stock Purchase Agreement, the 2022 RP Multi Tranche Loan Agreement Amendment and the RP Aficamten RPA Amendment
2026 Notes		Cytokinetics’ 4% convertible senior notes due 2026
2027 Indenture		Indenture Agreement, dated July 6, 2022, between Cytokinetics and U.S. Bank Trust Company, as trustee
2027 Notes		Cytokinetics’ 3.50% convertible senior notes due 2027
ACA		Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACACIA-HCM		Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM
ACC		American College of Cardiology
AHA		American Heart Association
ALS		amyotrophic lateral sclerosis (also known as Lou Gehrig’s Disease)
ALSFRS-R		ALS Functional Rating Scale – Revised
Amended ATM Facility		amended and restated Controlled Equity Offering Sales Agreement
Amgen Agreement		Collaboration and Option Agreement, dated December 29, 2006, as amended, between Cytokinetics and Amgen
ARR		absolute risk reductions
Astellas Agreement		License and Collaboration Agreement, dated June 21, 2013, between Cytokinetics and Astellas
Astellas FSRA Agreement		Fast Skeletal Regulatory Activator Agreement, dated April 23, 2020 between Cytokinetics and Astellas
Astellas OSSA Agreement		License and Collaboration Agreement for Other Skeletal Sarcomere Activators, dated April 23, 2020, as amended, between Cytokinetics and Astellas
cGMP		current Good Manufacturing Practice
Cantor		Cantor Fitzgerald & Co.
China		People's Republic of China (including the Hong Kong and Macau SARs)
CMC		Chemistry, Manufacturing and Controls
CMO		Contract Manufacturing Organizations
Common Stock		our common stock, par value $0.001 per share
Compensation Committee		Compensation and Talent Committee of Cytokinetics’ Board of Directors
Convertible Notes		2026 Notes and 2027 Notes

Table of Contents


COURAGE-ALS		Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS
CPET		cardiopulmonary exercise testing
CRL		Complete Response Letter
CRO		Contract Research Organization
CV		cardiovascular
E.U. or EU		European Union
EEA		European Economic Area
EMA		European Medicines Agency
ESPP		employee stock purchase plan
Exchange Act		Securities Exchange Act of 1934, as amended
FDA		U.S. Food and Drug Administration
Final Payment Amount		As defined in Part I, Item 2 (Management’s Discussion and Analysis of Financial Conditions and Results of Operations) of this Quarterly Report on Form 10-Q – Sources and Uses of Cash, Royalty Pharma Transactions
FOREST-HCM		Five-Year, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM
FSRA		fast skeletal regulatory activator
FSTA		fast skeletal muscle troponin activator
Fundamental Change		As defined in the 2027 Indenture
GAAP		Generally Accepted Accounting Principles in the U.S.
GALACTIC-HF		Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure
GCP		Good Clinical Practice
GDPR		General Data Protection Regulation ((EU) 2016/679)
HCM		hypertrophic cardiomyopathy
HFpEF		heart failure with preserved ejection fraction
HFrEF		heart failure with reduced ejection fraction
HFSA		Heart Failure Society of America
HHS		U.S. Department of Health and Human Services
HIPAA		The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act
ICER		Institute for Clinical and Economic Review
IND		Investigational New Drug
IRA		Inflation Reduction Act of 2022
IRB		Institutional Review Board
Corxel		Corxel Pharmaceuticals Limited (f/k/a JiXing Pharmaceuticals Limited) and/or its affiliates, including Corxel Pharmaceuticals Hong Kong Limited
Corxel Aficamten License Agreement		License and Collaboration Agreement, dated July 14, 2020, by and between Cytokinetics and Corxel Pharmaceuticals Limited
Corxel Agreements		Corxel Aficamten License Agreement and Corxel OM License Agreement
Corxel OM License Agreement		License and Collaboration Agreement, dated December 20, 2021, by and between Cytokinetics and Corxel Pharmaceuticals Limited
KCCQ		Kansas City Cardiomyopathy Questionnaire
KCCQ-OSS		KCCQ Overall Summary Score
Lenders		Silicon Valley Bank and Oxford Finance LLC

Table of Contents


LVEF		left ventricular ejection fraction
LVOT		left ventricular outflow tract
LVOT-G		left ventricular outflow tract gradient
MAA		Marketing Authorization Application
MAPLE-HCM		Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Endpoints Capacity in HCM
Mavacamten Royalty		certain payments on the net sales of products containing the compound mavacamten pursuant to the Research Collaboration Agreement, dated August 24, 2012, between Cytokinetics and MyoKardia, Inc.
NDA		New Drug Application
nHCM		non-obstructive HCM
NOLs		net operating loss carryforward
NYHA		New York Heart Association
oHCM		obstructive HCM
OLE		Open-Label Extension
Ownership Change		As defined in Part II, Item 1A (Risk Factors) of this Quarterly Report on Form 10-Q, General Risks
Oxford		Oxford Finance LLC
Oyster Point Lease		Lease, dated July 24, 2019, by and between Cytokinetics and KR Oyster Point 1, LLC, as amended
Partial Redemption Limitation		As defined in the 2027 Indenture
PSU		Performance Stock Unit
Radnor Lease		As defined in Part I, Item 1 (Financial Statements (Unaudited)), Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q - Note 9 (Commitments and Contingencies) – Operating Leases
REDWOOD-HCM		Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM
REDWOOD-HCM OLE		Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM Open Label Extension
REMS		Risk Evaluation and Mitigation Strategy
RP Aficamten RPA		Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between Cytokinetics and Royalty Pharma Investments 2019 ICAV
RP Aficamten RPA Amendment		Amendment No. 1, dated May 22, 2024, to Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between Cytokinetics and Royalty Pharma Investments 2019 ICAV
RP CK-586 RPA		CK-586 Revenue Participation Right Purchase Agreement, dated May 22, 2024, by and between Cytokinetics and Royalty Pharma Investments 2019 ICAV
RP Multi Tranche Loan Agreement		Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and Cytokinetics
RP Multi Tranche Loan Agreement Amendment		Third Amendment, dated May 22, 2024, to Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and Cytokinetics
RP OM Liability		As defined in Part I, Item 1 (Financial Statements (Unaudited)), Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q - Note 6 (Agreements with Royalty Pharma) – 2017 RP Omecamtiv Mecarbil Royalty Purchase Agreement
RP OM Loan Agreement		2024 Development Funding Loan Agreement, dated May 22, 2024, by and among Royalty Pharma Development Funding, LLC and Cytokinetics
RP OM RPA		Royalty Purchase Agreement, dated February 1, 2017, by and between the Cytokinetics and RPI Finance Trust, as amended by Amendment No. 1, dated January 7, 2022

Table of Contents


RP Stock Purchase Agreement		Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Cytokinetics and Royalty Pharma Investments 2019 ICAV
RPDF		Royalty Pharma Development Funding, LLC
RPFT		RPI Finance Trust
RPI ICAV		Royalty Pharma Investments 2019 ICAV
RSU		Restricted Stock Unit
RTW ICAV		RTW Investments ICAV for RTW Fund 1
RTW Investors		RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited
RTW Royalty Holdings		RTW Royalty Holdings Designated Activity Company
RTW Royalty Purchase Agreement		Royalty Purchase Agreement, dated July 14, 2020, between Cytokinetics and RTW Royalty Holdings
Section 382		Section 382 of the Internal Revenue Code
Securities Act		Securities Act of 1933, as amended
SEQUOIA-HCM		Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM
SGLT2		sodium-glucose cotransporter-2
SMA		spinal muscular atrophy
SPA		Special Protocol Assessment
Tax Act		Tax Cuts and Jobs Act
Term Loan Agreement		Loan and Security Agreement, dated as of October 19, 2015, by and among Cytokinetics, Oxford Finance LLC and Silicon Valley Bank and Loan and Security Agreement, dated as of May 17, 2019, by and among Cytokinetics, Oxford Finance LLC and Silicon Valley Bank
U.S. or US		United States

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

CYTOKINETICS and our C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Other service marks, trademarks and trade names referred to in this report are the property of their respective owners.

The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CYTOKINETICS, INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands) (Unaudited)


	September 30, 2024			December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	46,888		$	113,024
Short-term investments		964,804			501,800
Accounts receivable		244			1,283
Prepaid expenses and other current assets		6,665			11,944
Total current assets		1,018,601			628,051
Long-term investments		269,168			40,534
Property and equipment, net		64,222			68,748
Operating lease right-of-use assets		76,344			78,987
Other assets		7,725			7,996
Total assets	$	1,436,060		$	824,316
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	11,581		$	21,507
Accrued liabilities		49,826			42,641
Short-term operating lease liabilities		18,856			17,891
Current portion of long-term debt		11,520			10,080
Derivative liabilities measured at fair value		12,500			—
Other current liabilities		5,529			10,559
Total current liabilities		109,812			102,678
Term loans, net		93,017			58,384
Convertible notes, net		551,481			548,989
Liabilities related to revenue participation right purchase agreements, net		448,509			379,975
Long-term operating lease liabilities		114,752			120,427
Liabilities related to RPI Transactions measured at fair value		132,400			—
Other non-current liabilities		—			186
Total liabilities		1,449,971			1,210,639
Commitments and contingencies
Stockholders' deficit
Preferred stock		—			—
Common stock		118			102
Additional paid-in capital		2,532,328			1,725,823
Accumulated other comprehensive income (loss)		5,387			(10	)
Accumulated deficit		(2,551,744	)		(2,112,238	)
Total stockholders' deficit		(13,911	)		(386,323	)
Total liabilities and stockholders' deficit	$	1,436,060		$	824,316

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CYTOKINETICS, INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except per share data) (Unaudited)


	Three Months Ended						Nine Months Ended
	September 30, 2024			September 30, 2023			September 30, 2024			September 30, 2023
Revenues:
Research and development revenues	$	463		$	378		$	1,547		$	3,358
Milestone revenues		—			—			—			2,500
Total revenues		463			378			1,547			5,858
Operating expenses:
Research and development		84,612			82,532			245,779			245,147
General and administrative		56,652			40,111			152,976			129,498
Total operating expenses		141,264			122,643			398,755			374,645
Operating loss		(140,801	)		(122,265	)		(397,208	)		(368,787	)
Interest expense		(8,928	)		(7,136	)		(28,763	)		(21,142	)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements		(13,370	)		(6,860	)		(35,155	)		(19,462	)
Interest and other income, net		17,054			6,839			36,520			20,043
Change in fair value of derivative liabilities		700			—			100			—
Change in fair value of liabilities related to RPI Transactions		(15,200	)		—			(15,000	)		—
Net loss	$	(160,545	)	$	(129,422	)	$	(439,506	)	$	(389,348	)
Net loss per share — basic and diluted	$	(1.36	)	$	(1.35	)	$	(4.00	)	$	(4.07	)
Weighted-average number of shares used in computing net loss per share — basic and diluted		117,685			96,071			109,932			95,666
Other comprehensive (loss) gain:
Unrealized gain on available-for-sale securities, net		6,535			584			5,480			2,716
Foreign currency translation adjustments		(126	)		—			(83	)		—
Comprehensive loss	$	(154,136	)	$	(128,838	)	$	(434,109	)	$	(386,632	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CYTOKINETICS, INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (Deficit) EQUITY

(In thousands, except share data) (Unaudited)


	Common Stock					Additional Paid-In			Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares			Amount		Capital			Income (Loss)			Deficit			(Deficit) Equity
Balance, December 31, 2023		101,637,922		$	102	$	1,725,823		$	(10	)	$	(2,112,238	)	$	(386,323	)
Exercise of stock options		1,466,359			2		29,530			—			—			29,532
Vesting of restricted stock units		695,140			—		—			—			—			—
Shares withheld related to net share settlement of equity awards		(274,256	)		—		(18,449	)		—			—			(18,449	)
Issuance of common stock under at-the-market offering, net of issuance costs		1,237,460			1		93,639			—			—			93,640
Exercise of warrants, net		11,335			—		—			—			—			—
Stock-based compensation		—			—		21,612			—			—			21,612
Other comprehensive loss		—			—		—			(529	)		—			(529	)
Net loss		—			—		—			—			(135,643	)		(135,643	)
Balance, March 31, 2024		104,773,960			105		1,852,155			(539	)		(2,247,881	)		(396,160	)
Exercise of stock options		356,281			—		8,007			—			—			8,007
Vesting of restricted stock units		46,034			—		—			—			—			—
Issuance of common stock under Employee Stock Purchase Plan		93,857			—		2,678			—			—			2,678
Issuance of common stock in public offering, net of issuance costs		11,274,510			11		563,193			—			—			563,204
Issuance of common stock in private placement, net of issuance costs		980,392			1		49,999			—			—			50,000
Stock-based compensation		—			—		24,622			—			—			24,622
Other comprehensive loss		—			—		—			(483	)		—			(483	)
Net loss		—			—		—			—			(143,318	)		(143,318	)
Balance, June 30, 2024		117,525,034			117		2,500,654			(1,022	)		(2,391,199	)		108,550
Exercise of stock options		362,431			1		6,318						—			6,319
Vesting of restricted stock units		1,154			—		—			—			—			—
Stock-based compensation		—			—		25,356			—			—			25,356
Other comprehensive income		—			—		—			6,409			—			6,409
Net loss		—			—		—			—			(160,545	)		(160,545	)
Balance, September 30, 2024		117,888,619		$	118	$	2,532,328		$	5,387		$	(2,551,744	)	$	(13,911	)

Table of Contents


	Common Stock					Additional Paid-In			Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares			Amount		Capital			Loss			Deficit			Deficit
Balance, December 31, 2022		94,833,975		$	94	$	1,481,590		$	(3,590	)	$	(1,585,994	)	$	(107,900	)
Exercise of stock options		369,298			—		3,547			—			—			3,547
Vesting of restricted stock units		668,835			—		—			—			—			—
Shares withheld related to net share settlement of equity awards		(262,829	)		—		(10,517	)		—			—			(10,517	)
Stock-based compensation		—			—		15,194			—			—			15,194
Other comprehensive income		—			—		—			1,945			—			1,945
Net loss		—			—		—			—			(131,289	)		(131,289	)
Balance, March 31, 2023		95,609,279			94		1,489,814			(1,645	)		(1,717,283	)		(229,020	)
Exercise of stock options		206,605			—		3,286			—			—			3,286
Vesting of restricted stock units		46,989			—		—			—			—			—
Issuance of common stock under Employee Stock Purchase Plan		74,937			—		2,401			—			—			2,401
Stock-based compensation		—			—		18,668			—			—			18,668
Other comprehensive income		—			—		—			187			—			187
Net loss		—			—		—			—			(128,637	)		(128,637	)
Balance, June 30, 2023		95,937,810			94		1,514,169			(1,458	)		(1,845,920	)		(333,115	)
Exercise of stock options		273,149			—		3,124			—			—			3,124
Vesting of restricted stock units		2,454			—		—			—			—			—
Issuance of common stock under at-the-market offering, net of issuance costs		38,431			—		1,312			—			—			1,312
Stock-based compensation		—			—		18,716			—			—			18,716
Other comprehensive income		—			—		—			584			—			584
Net loss		—			—		—			—			(129,422	)		(129,422	)
Balance, September 30, 2023		96,251,844		$	94	$	1,537,321		$	(874	)	$	(1,975,342	)	$	(438,801	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CYTOKINETICS, INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)


	Nine Months Ended
	September 30, 2024			September 30, 2023
Cash flows from operating activities:
Net loss	$	(439,506	)	$	(389,348	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense on liabilities related to revenue participation right purchase agreements		35,233			19,548
Stock-based compensation expense		71,590			52,578
Non-cash lease expense		3,152			2,808
Depreciation of property and equipment		7,148			5,557
Change in fair value of derivative liabilities		(100	)		—
Change in fair value of liabilities related to RPI Transactions		15,000			—
Realized gain on investment, net		—			35
Interest receivable and amortization on investments		(24,814	)		(10,634	)
Non-cash interest expense related to debt		8,027			20,950
Changes in operating assets and liabilities:
Accounts receivable		1,039			(2,352	)
Prepaid and other assets		6,006			(6,937	)
Accounts payable		(10,388	)		(11,194	)
Accrued and other liabilities		4,105			(15,026	)
Operating lease liabilities		(5,219	)		(272	)
Other non-current liabilities		(1,593	)		(6,009	)
Net cash used in operating activities		(330,320	)

CYTOKINETICS INC [CYTK] Filings
10-Q	[2024-11]
10-Q	[2024-08]
10-Q	[2024-05-10]
10-K	[2024-02-28]
10-Q	[2023-11-03]
10-Q	[2023-08-03]
10-Q	[2023-05-05]
10-K	[2023-03-01]
10-Q	[2022-11-04]
10-Q	[2022-08-05]
10-Q	[2022-05-06]
10-K	[2022-02-25]
10-Q	[2021-11-05]
10-Q	[2021-08-06]
10-Q	[2021-05-07]
10-K	[2021-02-26]
10-Q	[2020-11-06]
10-Q	[2020-08-07]
10-Q	[2020-05-08]
10-K	[2020-03-04]
10-Q	[2019-11-01]
10-Q	[2019-08-09]
10-Q	[2019-05-09]
10-K	[2019-03-07]
10-Q	[2018-11-09]
10-Q	[2018-08-07]
10-Q	[2018-05-10]
10-K	[2018-03-05]
10-Q	[2017-11-03]
10-Q	[2017-08-04]
10-Q	[2017-05-04]
10-K	[2017-03-06]
10-Q	[2016-11-03]
10-Q	[2016-08-04]
10-Q	[2016-05-05]
10-K	[2016-03-03]
10-Q	[2015-11-05]
10-Q	[2015-08-05]
10-Q	[2015-05-04]
10-K	[2015-03-06]
10-Q	[2014-11-06]
10-Q	[2014-08-07]
10-Q	[2014-05-07]
10-K	[2014-03-07]
10-Q	[2013-11-06]
10-Q	[2013-08-07]
10-Q	[2013-05-08]
10-K	[2013-03-15]
10-Q	[2012-11-07]
10-Q	[2012-08-06]
10-Q	[2012-05-04]
10-K	[2012-03-13]